Fiduciary Group LLC boosted its position in shares of CVS Health Corp (NYSE:CVS) by 5.6% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,750 shares of the pharmacy operator’s stock after buying an additional 200 shares during the quarter. Fiduciary Group LLC’s holdings in CVS Health were worth $222,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds also recently modified their holdings of CVS. Wealth Quarterback LLC purchased a new stake in shares of CVS Health during the fourth quarter valued at $12,665,010,000. Norges Bank purchased a new stake in shares of CVS Health during the fourth quarter valued at $955,672,000. Capital World Investors boosted its stake in shares of CVS Health by 744.2% during the fourth quarter. Capital World Investors now owns 10,974,728 shares of the pharmacy operator’s stock valued at $815,313,000 after purchasing an additional 9,674,728 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its stake in shares of CVS Health by 468.4% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,042,981 shares of the pharmacy operator’s stock valued at $224,325,000 after purchasing an additional 2,507,659 shares during the period. Finally, Veritas Asset Management LLP boosted its stake in shares of CVS Health by 32.1% during the first quarter. Veritas Asset Management LLP now owns 10,235,658 shares of the pharmacy operator’s stock valued at $607,282,000 after purchasing an additional 2,487,300 shares during the period. 76.44% of the stock is owned by hedge funds and other institutional investors.
NYSE:CVS traded down $0.01 during midday trading on Friday, hitting $63.33. The company’s stock had a trading volume of 3,494,416 shares, compared to its average volume of 8,148,172. CVS Health Corp has a fifty-two week low of $52.04 and a fifty-two week high of $77.03. The firm’s 50 day moving average is $61.11 and its 200-day moving average is $67.62. The company has a debt-to-equity ratio of 1.29, a current ratio of 0.99 and a quick ratio of 0.70. The firm has a market cap of $82.79 billion, a P/E ratio of 11.47, a P/E/G ratio of 1.42 and a beta of 0.73.
The firm also recently declared a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were issued a $0.50 dividend. The ex-dividend date of this dividend was Wednesday, April 22nd. This represents a $2.00 annualized dividend and a yield of 3.16%. CVS Health’s dividend payout ratio (DPR) is presently 28.25%.
In other CVS Health news, SVP James David Clark sold 3,030 shares of the company’s stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $60.00, for a total value of $181,800.00. Following the sale, the senior vice president now owns 12,790 shares in the company, valued at approximately $767,400. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Alan Lotvin acquired 5,000 shares of the stock in a transaction on Monday, May 11th. The stock was bought at an average price of $63.14 per share, for a total transaction of $315,700.00. Following the transaction, the executive vice president now owns 15,161 shares in the company, valued at approximately $957,265.54. The disclosure for this purchase can be found here. 0.46% of the stock is currently owned by corporate insiders.
A number of analysts have recently issued reports on the stock. Robert W. Baird boosted their target price on shares of CVS Health from $62.00 to $66.00 and gave the company a “neutral” rating in a research note on Thursday, May 7th. Tigress Financial reissued a “buy” rating on shares of CVS Health in a research note on Friday, April 24th. Cantor Fitzgerald upped their price objective on shares of CVS Health from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $77.00 price objective on shares of CVS Health in a research note on Wednesday, May 6th. Finally, Oppenheimer reaffirmed a “hold” rating on shares of CVS Health in a research note on Wednesday, May 6th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, fifteen have assigned a buy rating and two have given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $80.88.
About CVS Health
CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.
See Also: What is a Stop Order?
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.